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Objective: Individual sensitivity to recombinant human GH (r-hGH) is variable. Identification of genetic
factors contributing to this variability has potential use for individualization of treatment. The
objective of this study was to identify genetic markers and gene expression profiles associated with
growth response on r-hGH therapy in treatment-naı¨ve, prepubertal children with GH deficiency (GHD)
or Turner syndrome (TS).
Design: A prospective, multicenter, international, open-label pharmacogenomic study.
Methods: The associations of genotypes in 103 growth- and metabolism-related genes and baseline
gene expression profiles with growth response to r-hGH (cm/year) over the first year were evaluated.
Genotype associations were assessed with growth response as a continuous variable and as a
categorical variable divided into quartiles.
Results: Eleven genes in GHD and ten in TS, with two overlapping between conditions, were
significantly associated with growth response either as a continuous variable (seven in GHD, two in TS)
or as a categorical variable (four more in GHD, eight more in TS). For example, in GHD, GRB10 was
associated with high response (RQ3; PZ0.0012), while SOS2 was associated with low response
(%Q1; PZ0.006), while in TS, LHX4 was associated with high response (PZ0.0003) and PTPN1 with
low response (PZ0.0037). Differences in expression were identified for one of the growth response-
associated genes in GHD (AKT1) and for two in TS (KRAS and MYOD1).
Conclusions: Carriage of specific growth-related genetic markers is associated with growth response in
GHD and TS. These findings indicate that pharmacogenomics could have a role in individualized
management of childhood growth disorders.
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Recombinant human GH (r-hGH) has proved to be a safe
and effective treatment to increase growth rate and adult
height across a range of growth disorders, and improve
metabolic status in adult GH deficiency (GHD) (1, 2).
There is, however, substantial interindividual variability
in growth response to r-hGH (1), and health economic
assessments have shown that variability in response to
r-hGH is the most important factor determining the cost-
effectiveness of treatment (3, 4, 5). Licensing authorities
recognize that the posology of r-hGH needs to be
individualized. Predicting growth response to r-hGHne.organd personalizing dosing should, therefore, be a clinical
priority. Beyond conventional growth predictors (e.g.
age, weight and r-hGH dose at the start of treatment),
the identification of genetic factors contributing to this
variability can be used to promote individualization of
GH (r-hGH) treatment for best patient outcome.
There are many pathways that regulate human
growth, which include hormones, growth factors and
cellular growth processes (6, 7). Polymorphisms that
could alter the function of the genes in these pathways
may affect growth response to r-hGH therapy. One such
example is the GH receptor polymorphism, in which
exon 3 is either present or absent. This has been shownThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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response to r-hGH in vivo (8): in meta-analyses, those
who carry the exon 3 deletion grow more (byw1 cm in
the first year) in response to r-hGH (9, 10). However,
these meta-analyses demonstrate significant variation
between reports on one condition, and between
conditions. This highlights the limitations of studying
the effect of a single gene on a complex trait, such as
growth. Another approach to assessing r-hGH respon-
siveness, which uses a whole genome rather than
candidate gene methodology, is to examine gene
expression profiles. Using peripheral blood mononuclear
cells (PBMCs) as the RNA source, this has generated
data relevant to growth responses to r-hGH in children
with GHD and Turner syndrome (TS), and in adults to
detect r-hGH doping (11, 12). To date, a large-scale
study in children with growth disorders has not been
undertaken to address this important issue.
Pharmacogenomics has been successfully used in the
field of cancer to identify benign vs malignant tumors
and to quantify the risk of tumor recurrence (13, 14).
Testing of specific genes is being used increasingly to
predict response to drugs: the results of such tests can
indicate whether a drug should not be used because of
the risk of adverse events, or whether the dose to
achieve a safe and efficacious outcome should be
modified (15). In some instances, genetic testing has
become part of the license requirements issued by
regulatory authorities for use of a drug (15).
The PREDICTstudy (NCT00256126; Merck Serono S.A.,
Study 24531: A Phase IV Open-label Study of Predictive
Markers in Growth Hormone Deficient and Turner
Syndrome Pre-pubertal Children Treated with SAIZENw)
was a month-long trial to identify the most responsive
serum biomarkers associated with growth response to
r-hGH therapy. Two conditions, associated with significant
short stature and well-characterized growth responses to
r-hGH, were assessed, namely GHD and TS, which together
account forw50% of r-hGH prescriptions.
The study presented here (NCT00699855; Merck
Serono S.A., Study 28614: Observational Long-term
Follow-up of the Phase IV Open-label Trial of Predictive
Markers in Growth Hormone-Deficient and Turner
Syndrome Pre-pubertal Children Treated with SAIZENw)
constitutes the first-year results following on from the
PREDICT study, which uses a pharmacogenomic
approach to evaluate the association of genetic poly-
morphisms in growth- and metabolism-related genes
and baseline gene expression profiles using whole blood
mRNA with long-term changes in growth while on
r-hGH therapy. The objective of this study was to identify
genetic markers and gene expression profiles associated
with growth response (cm) 1 year after the initiation of
r-hGH therapy in treatment-naı¨ve prepubertal children
with GHD or TS. This study demonstrates that a broad
range of genes, related in particular to cell signaling, are
associated with growth response to r-hGH. It also shows
that the associated genes differ between GHD and TS,www.eje-online.organd that these genetic markers and expression profiles
are associated with high or low first-year growth
responses to r-hGH in children with GHD or TS. This
work indicates that pharmacogenomics could be used to
predict a key outcome of r-hGH treatment.Subjects and methods
Study design
This open-label, prospective study involved three steps.
First, candidate genes involved in growth and metab-
olism were identified by a literature search and selected
for inclusion based on advice from a board of growth
experts (see online Supplementary Table 1, see section
on supplementary data given at the end of this article for
a list of the candidate genes). Then, individual genotypes
were assessed for their effect on growth (using full
genotype, as well as dominant and recessive models for
carriers of major and minor alleles), and associated
markers were identified. Finally, the predictive potential
of these markers was evaluated by categorizing the
patient population into three groups based on height
change in three age bands (!8, 8–12 andO12 years):
high (O75th percentile (RQ3)), intermediate (between
the 25th and 75th percentiles (OQ1–!Q3)) and low (!
25th percentile (%Q1)). Analysis was carried out
separately for patients with GHD and TS.
This study was conducted in compliance with ethical
principles based on the Declaration of Helsinki, the
International Conference on Harmonization Tripartite
Guideline for Good Clinical Practice, and all applicable
regulatory requirements.Patients and treatment interventions
In total, 170 patients (110 with GHD and 60 with TS)
underwent a genetic analysis from a per-protocol
population at 1 year of 182 patients (115 with GHD
and 67 with TS). The patients were recruited in
14 countries from across the world (listed under the
Acknowledgements section). All the patients were
prepubertal at the start of treatment. The diagnosis of
GHD was based on two different stimulation tests with a
peak GH value !10 mg/l, using assays in the local
center. Patients selected for r-hGH treatment were based
on criteria used in the local units. Patients with GHD
associated with etiologies such as CNS tumors with or
without cranial irradiation were excluded. The median
peak GH value was 4.1 mg/l (Table 1), and!25% of the
patients had a valueO5.6 mg/l, and only eight patients
had a peak GH value between 7 and 10 mg/l. TS
required karyotype confirmation. Patients with GHD
received r-hGH at an average dose of 0.035 mg/kg per
day, and patients with TS received an average dose of
0.051 mg/kg per day. Other hormone deficiencies
(cortisol and thyroxine), if present, were appropriately
treated. Compliance was monitored by recall in the last
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Table 1 Patient demographic data at baseline. Data are number (%) or median (Q1 and Q3). Minimum and maximum values
are shown in brackets.
Per-protocol
population at year 1 GHD (nZ115) Min, max values TS (nZ67) Min, max values
Male (%) 69 (60)a 0 (0)
Female (%) 46 (40)a 67 (100)a
Age (years) 9.8 (6.8, 11.3) 2, 15 9.1 (6.3, 11.8) 3, 16
Mid-parental height SDS K0.8 (K1.6,K0.1) K4,C2 K0.1 (K0.9, 0.6) K4,C2
Height SDS K2.1 (K2.7,K1.7) K6.5,K0.3 K2.4 (K3.1,K1.5) K5.4,K0.2
BMI SDS K0.3 (K1.0,C0.5) K3,C10.3 C0.6 (K0.3,C1.6) K2.2,C4.8
GH peak response (mg/l) 4.1 (2.6, 5.6) 0, 9 NA
IGF1 SDS K1.8 (K2.8,K0.9) K7.7,C1.1 K1.2 (K2.1,K0.5) K4.5,C1.7
IGFBP3 SDS K0.2 (K1.1,C0.5) K5.3,C2.2 C0.3 (K0.2,C0.7) K2.3,C2.1
GHD, GH deficiency; IGFBP3, insulin-like growth factor binding protein 3; NA, not applicable; Q, quartile; TS, Turner syndrome.
aAll were Tanner stage 1 at baseline. Thirty-seven children with GHD and 12 girls with TS entered puberty over the first year. DNA samples for
genotyping were available for 110 patients with GHD and 60 girls with TS.
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w90% in both conditions.
Growth parameters were converted to SDS using the
Sempe´ reference data (16), so that all children were
compared with the same standard. Baseline insulin-like
growth factor 1 (IGF1) and IGF binding protein 3
(IGFBP3) were measured in a central laboratory (qLAB,
Livingston, Edinburgh, UK), using the DPC chemi-
luminescent immunoassay (Immunolite 2000; Siemens
Healthcare Diagnostics, Norwood, MA, USA). Levels
were converted to SDS using relevant reference data
(17). Baseline characteristics are shown in Table 1.Genetic analysis
Genotyping was performed centrally on DNA extracted
from whole blood using an Illumina GoldenGate micro
array, containing 1536 single nucleotide polymorph-
isms (SNPs) located in 103 candidate genes related to
i) the GH/IGF1 axis, ii) bone and cell growth and
iii) glucose and lipid metabolisms. A total of 1451 SNPs
were successfully genotyped. Prior to analysis, the
genotyping data for these SNPs were filtered to remove
SNPs with low minor allele frequency (!10%), those
with a call rate below 95%, and those (except for
X-linked SNPs in girls with TS and boys with GHD)
showing significant deviation from the Hardy–
Weinberg equilibrium using a Bonferroni correction
for 1451 tests. After this cleaning step, 1182 SNPs in
patients with GHD and 1183 SNPs in patients with TS
remained for analysis. All analyses were performed
centrally by the Bioinformatics Group at Merck Serono.
Gene expression profiling was carried out on whole
blood RNA extracted centrally by qLAB using the
PAXgene 96 blood RNA Kit (Qiagen) at baseline:
67 samples were available for GHD and 44 for TS.
Reduction of globin mRNA was undertaken using the
Ambion GLOBIN clear Human Kit (Life Technologies).
The quality of RNA was assessed using an ND-1000
spectrophotometer (NanoDrop, Wilmington, DE, USA)
and qualified using an Agilent 2100 Bioanalyzer(Agilent Technologies, Santa Clara, CA, USA). cRNA
was generated using the Two-Cycle Eukaryotic Target
Labeling Kit (Affymetrix, Santa Clara, CA, USA) and a
final quality check was performed before hybridization
to Affymetrix GeneChip Human Genome U133 Plus 2.0
Arrays. Arrays were then scanned on an Affymetrix
GeneChip 3000 7G scanner and assessed for quality
against internal and hybridization controls. All analyses
were performed centrally by the Bioinformatics Group
at Merck Serono.
Processing and normalization of the raw gene
expression data were performed on GHD and TS samples
using a Robust Multi-array Average background correc-
tion modified for probe sequence with quantile normal-
ization and median polish (Partek Genomics Suite
version 6.3, Partek Inc., St. Louis, MO, USA). Outliers
were identified by cross-validation using principal
component analysis (PCA) and Isomap multidimensional
scaling (Qlucore Omics Explorer 2.2, Qlucore AB, Lund,
Sweden) to generate first-year growth response datasets
in GHD and TS. A variance cut-off relative to the variable
with the largest variance (smax) was used to remove
noninformative probes; this was set at 0.05 s/smax
(Qlucore Omics Explorer 2.2). All processing of array
data was performed at the University of Manchester.Statistical analysis
Continuous analysis SNPs associated with first-year
growth were identified using the Kruskal–Wallis rank
sum test on the genotype (additive model), the presence
or the absence of the major allele (dominant model) and
the presence or the absence of the minor allele (recessive
model). For nonpseudoautosomal X-linked markers,
boys with GHD were analyzed separately from girls with
GHD. As a candidate gene, rather than a whole genome,
approach was being used, both unadjusted P values and
adjusted P values calculated using a Bonferroni
correction that takes into account the number of
linkage disequilibrium (LD) blocks present in the gene
containing the SNP are reported for each SNP.www.eje-online.org
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second stage of the analysis, where patients were
classified by quartiles, based on the normal distribution
of growth response, as high (RQ3), intermediate
(OQ1–!Q3) or low responders (%Q1) in each of
three age groups (!8, 8–12 andO12 years) to control
for the potential impact of age on response to r-hGH.
Markers were assessed by comparing high responders vs
intermediateClow responders, and low responders vs
intermediateChigh responders. All P values were
calculated using Fisher’s exact test and are shown as
both unadjusted and Bonferroni-corrected values using
the number of LD blocks within each candidate gene.
All demographic and growth data were analyzed by
the Biostatistics Group at Merck Serono. Both the
continuous and categorical analyses were conducted by
Genizon BioSciences (Montreal, QC, Canada).
Country of origin analysis In order to address
whether country of origin or population stratification
may be a confounding factor in response to r-hGH, a PCA
was undertaken using the PLINK genetic analysis
software (http://pngu.mgh.harvard.edu/wpurcell/
plink/) by PGx Services. The genotypes for the 1182
GHD and 1183 TS SNPs were first screened to produce
Tag SNPs that were in linkage equilibrium (R2!0.2 for
LD between any two Tag SNPs). This was performed
twice, independently, to generate lists of Tag SNPs for
GHD and TS, on which PCA was carried out. The first two
PCs were then used to assess impact on growth response.
Gene expression profiles Gene expression associated
with first-year growth response (cm) in GHD and TS was
identified in low vs intermediateChigh responders, and
in high vs intermediateClow responders (as defined
above) using ANOVA (P!0.05), with control for gender
and age. Control for age was undertaken as we have
recently shown that gene expression in healthy children
is age dependent (18). In order to better understand the
function and significance of these growth-associated
genes, the analysis of inferred protein–protein
interaction networks was performed using Ingenuity
Pathways Analysis (IPA) Software. This allows differen-
tially expressed genes to be correlated with biologic
pathways. IPA was also used to generate inferred
interaction networks derived from the genes associated
with growth response. Gene expression data were then
mapped onto these inferred networks to allow the
integration of gene expression and genetic analyses, and
to assess the presence of putative expression quan-
titative trait loci (eQTL). All analyses of array data were
performed at the University of Manchester.
In silico evaluation of predicted function for
significant SNPs The predicted consequences of an
SNP on transcriptional activity have been derived based
on data from many different cell lines in whichwww.eje-online.orgtranscription factors and their binding sites responsible
for modulating gene transcription, as identified by
chromatin immunoprecipitation sequencing (ChIP-
seq), are listed in the Encyclopaedia of DNA Elements
(ENCODE) database (http://genome.ucsc.edu/ENCODE/)
(19). Using this database, SNPs associated with growth
response to r-hGH in this study, which lie in or near these
binding sites and have been shown to have an impact on
transcription, were identified.Results
Genetic markers and expression profiles
associated with height change in children
with GHD
The children with GHD had a median basal growth rate
of 4 (Q1, 3; Q3, 6) cm/year, and then grew a median of
8.5 (Q1, 7.3; Q3, 10.2) cm over the first year. Ten
polymorphisms within seven different genes were found
to be significantly associated with this growth response,
assessed as a continuous trait (Table 2). These included
the gene coding for the major GH-dependent carrier of
IGF1 in the circulation, IGFBP3; signaling molecules
GRB10 and SOS1 (MAPK pathway); the phosphatase
INPPL1; the growth factor TGFa the tumor suppressor
TP53; and CYP19A1, a P450 cytochrome enzyme with
aromatase activity. For each polymorphism, the
difference in growth between alleles or genotypes was
O1 cm over the first year, representing w20% of first-
year increment in growth.
To control for the potential impact of age on growth
response, genes associated with growth, defined as high
(RQ3), intermediate (OQ1–!Q3) or low responders
(%Q1) in each of three age groups, were identified.
Four of the genes in the continuous trait analysis were
also found by this categorical analysis (Table 3), while a
further four genes were added: IGFII (IGF2), CYR61
(a secreted protein, also known as IGFBP10), AKT1
(a signaling molecule activated by PI3K) and SOS2
(MAPK signaling). Importantly, the r-hGH doses between
the high, intermediate and low responders did not differ
(Table 4). To control for the potential impact of country of
origin on response, a PCA was undertaken. The first
principal component (PC) based on the Tag SNPs clearly
separated those children from Asia from all other
children (Fig. 1A). However, there was complete overlap
in growth response between the groups (Fig. 1B).
A total of 1886 gene expression probe sets
corresponding to 1188 genes (Ingenuity Knowledge
Base) were associated with first-year growth in the
expression profiles for the low responder analysis
(Fig. 2A): a distinct pattern of gene expression at
baseline in the low responders compared with the other
profiles was identified. A total of 1127 gene expression
probe sets corresponding to 865 genes (Ingenuity
Knowledge Base) were associated with the high
responder analysis with the expression profile in the
AUTHOR COPY ONLY
Table 2 Single nucleotide polymorphisms (SNPs) in genes associated with first-year growth response in (A) GHD and (B) TS. Mean height
change for genotypes is shown. More than one SNP was associated with growth for IGFBP3, GRB10, TGFa and INPPL1.
Gene Function SNP ID Model Genotype (n)
Mean height
change, cm
(S.D.)
Nonadjusted
P value
Adjusted
P value
GHD
GRB10 Insulin and IGF1
signaling
rs1024531 Genotype GG (5) 6.2 (1.4) 0.0005 0.01
GA (45) 8.0 (2.0)
AA (60) 9.4 (1.9)
rs1024531 Allelea AA (60) 9.4 (1.9) 0.0006 0.0121
GG and GA (50) 7.9 (2.0)
rs12536500 Allelea CC (70) 9.2 (2.0) 0.001 0.0253
TT and TC (40) 7.9 (2.0)
rs933360 Allelea TT (71) 9.2 (2.2) 0.002 0.0448
TC and CC (39) 8.0 (1.6)
IGFBP3 Binding protein
for IGFs
rs3110697 Alleleb AA (18) 7.5 (2.0) 0.002 0.0117
GG and GA (91) 9.0 (2.1)
rs10255707 Alleleb CC and CT (92) 9.0 (2.1) 0.006 0.0278
TT (13) 7.3 (2.0)
rs3110697 Genotype AA (18) 7.4 (2.0) 0.009 0.0442
AG (42) 9.2 (2.1)
GG (49) 8.9 (2.0)
TGFa Growth factor rs958686 Genotype GG (14) 7.4 (1.0) 0.002 0.0351
GC (60) 8.6 (2.1)
CC (36) 9.6 (2.3)
rs958686 Allelea CC (36) 9.6 (2.3) 0.002 0.046
GG and GC (74) 8.0 (2.0)
CYP19A1 Aromatase
enzyme for
estrogen
synthesis
rs10459592 Allelea GG (29) 10 (2.2) 0.003 0.043
TT and TG (81) 8 (1.9)
SOS1 MAPK signaling
pathway
rs2888586 Allelea CC (33) 7.8 (1.8) 0.0095 0.0476
TT and CC (77) 9.0 (2.0)
TP53 Cell cycle
regulation
rs2909430 Allelea TT (77) 9.1 (2.1) 0.014 0.0414
TC and CC (33) 8.0 (1.8)
INPPL1 Regulation of
insulin and
growth factor
receptor
signaling
rs2276048 Allelea AA (72) 8.4 (1.9) 0.0254 0.0254
AG and GG (38) 9.5 (2.3)
rs2276048 Genotype AA (72) 8.4 (1.9) 0.0497 0.0497
AG (34) 9.4 (2.4)
GG (4) 10.1 (1.3)
TS
LHX4 Pituitary
transcription
factor
rs3845395 Allelea GG (31) 6.9 (1.4) 0.002 0.0485
GC and CC (29) 8.3 (1.8)
KRAS MAPK signaling
pathway
rs12579073 Genotype AA (22) 8.0 (1.7) 0.008 0.0461
AC (24) 6.8 (1.4)
CC (14) 8.4 (1.9)
aAllele, major allele recessive.
bAllele, major allele dominant.
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shown). Network analysis of the human interactome
associated with these genes indicated that glucocorti-
coid, estrogen and insulin receptor signaling, and
protein ubiquitination pathways were represented as
top canonical pathways (P!0.001).Genetic markers associated with height
change in girls with TS
Girls with TS had a median basal growth rate of 4
(Q1, 2; Q3, 6) cm/year, and then grew a median of 7.2(Q1, 6.1; Q3, 9.1) cm over the first year. Two
polymorphisms within two genes were found to be
significantly associated with this growth response,
assessed as a continuous trait (Table 2). These included
the signaling molecule KRAS (MAPK pathway) and the
pituitary transcription factor LHX4. As seen for GHD,
the difference in growth between different alleles or
genotypes was O1 cm over the first year.
LHX4, identified in the continuous trait analysis, was
also found in the categorical analysis. In contrast to
GHD, a further eight genes were added (Table 3):
IGFBP3 and SOS1 (MAPK signaling), both found inwww.eje-online.org
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Table 3 Genes identified using the categorical model, based on quartiles (Q) of growth response and age bands of (A) patients with GHD and (B) girls with TS.
Gene Function Marker
Categorical
model
Categorical
nonadjusted
P value
Categorical
adjusted
P value
Relative
risk
95% CI
relative risk Category 1 Category 2
Genotype
marker for
category 1
Genotype
marker for
category 2
(A) GHD
GRB10 Insulin and IGF1
signaling
rs1014384 Dominant 0.0012 0.0245 3.6 2.15, 5.94 L I C H GG AA and AG
GRB10a Insulin and IGF1
signaling
rs933360 Recessive 0.0012 0.0259 4.8 1.54, 14.73 H I C L TT CC and TC
GRB10 Insulin and IGF1
signaling
rs4521715 Recessive 0.0013 0.0266 4.6 1.48, 14.14 H I C L AA GG and AG
CYP19A1a Aromatase enzyme rs10459592 Recessive 0.0030 0.0455 2.6 1.44, 4.71 H I C L GG TT and TG
SOS2 MAPK signaling rs13379306 Recessive 0.0060 0.0482 2.4 1.31, 4.49 L I C H AA and AC CC
CYR61 Secreted protein,
IGFBP10
rs9658584 Recessive 0.0083 0.0167 2.7 1.26, 5.80 H I C L GG CC and CG
SOS1a MAPK signaling rs2888586 Recessive 0.0086 0.0429 3.7 1.21, 11.42 H I C L TT and TC CC
IGF2 Growth factor rs3213221 Dominant 0.0138 0.0414 2.5 1.36, 4.45 H I C L CC GG and CG
AKT1 Activated by PI3K rs1130214 Recessive 0.0290 0.0290 2.3 1.10, 4.68 L I C H AA and AC CC
INPPL1a Regulation of insulin
and growth factor
signaling
rs2276048 Recessive 0.0392 0.0392 2.0 1.10, 3.75 H I C L GG and AG AA
(B) TS
LHX4a Transcription factor rs3845395 Recessive 0.0003 0.0067 7.5 1.86, 30.11 H I C L CC and GC GG
LHX4 Transcription factor rs4652492 Recessive 0.0013 0.0275 NA NA H I C L AA and AG GG
PTPN1 Protein tyrosine
phosphatase (in
insulin and JAK2
signaling)
rs13041704 Dominant 0.0037 0.0261 4.7 2.83, 7.71 L I C H CC AA and AC
PIK3R3 Regulatory subunit
of PI3K
rs809775 Recessive 0.006 0.0181 3.3 1.51, 7.14 L I C H TT AA and AT
PPP1CB Catalytic subunit of
protein phospha-
tase 1
rs6725177 Recessive 0.006 0.0299 3.3 1.41, 7.86 L I C H CC GG and GC
CDK4 Cell cycle regulator rs2069502 Recessive 0.0073 0.0146 5.0 1.25, 20.07 H I C L TT and TC CC
SOS1 MAPK signaling rs2168043 Recessive 0.0079 0.0394 3.3 1.44, 7.33 H I C L AA and AC CC
IGFBP3 IGF binding protein rs3110697 Recessive 0.0084 0.0421 3.3 1.31, 8.30 L I C H GG AA and AG
TGFB1 Growth factor rs4803455 Recessive 0.0126 0.0379 NA NA H I C L AA and AC CC
MYOD1 Transcription factor
(in muscle)
rs3911833 Recessive 0.0476 0.0476 5.2 0.74, 36.47 L I C H CC TT and TC
GHD, GH deficiency; H, high responder (RQ3); I, intermediate responder (OQ1, !Q3); L, low responder (%Q1); NA, not applicable; Q, quartile; TS, Turner syndrome.
aGenes also identified in the continuous analysis.
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Table 4 Mean r-hGH doses in GHD and TS in those with high (RQ3), intermediate (OQ1,!Q3) or low responses (%Q1).
High Intermediate Low
GHD
Mean r-hGH dose (mg/kg per day) 0.0341 0.0350 0.0335
95% CI 0.0317–0.0365 0.0330–0.0371 0.0307–0.0364
Minimum, maximum values 0.0243, 0.0524 0.0164, 0.0563 0.0218, 0.0621
TS
Mean r-hGH dose (mg/kg per day) 0.0469 0.0482 0.0490
95% CI 0.0396–0.0541 0.0431–0.0533 0.0440–0.0517
Minimum, maximum values 0.0416, 0.0563 0.0375, 0.0607 0.0347, 0.0581
GHD, GH deficiency; r-hGH, recombinant human GH; Q, quartile; TS, Turner syndrome.
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signaling); CDK4 (a cell cycle regulator); TGFB1
(a growth factor); and MYOD1 (a muscle transcription
factor). Importantly, the r-hGH doses between the high,
intermediate and low responders did not differ (Table 4).
Similar to GHD, the first PC based on the Tag SNPs
separated those children from Asia from all other
children, with the exception of one child (Fig. 1C).
However, there was complete overlap in growth
response between the groups (Fig. 1D).
A total of 1003 gene expression probe sets
corresponding to 673 genes (Ingenuity Knowledge
Base) were associated with first-year growth in the
expression profiles for the low responder analysis
(Fig. 2B): a distinct pattern of gene expression at
baseline in the low responders compared with the other
profiles was identified. A total of 700 gene expression
probe sets corresponding to 506 genes (Ingenuity
Knowledge Base) were associated with the high
responder analysis with the expression profile in the
high responders differing from the rest (data not
shown). In contrast to GHD, no growth factor-related
canonical pathways were represented by these genes.Integration of genetic and gene expression data
To integrate the gene expression data with the genetic
analysis, inferred networks were generated from the
genetic data using the IPA functional association
algorithm. In children with GHD, this procedure
generated a network from all the associated genes
(AKT1, CYP19A1, CYR61, GRB10, IGF2, IGFBP3,
INPPL1, SOS1, SOS2 and TGFa with the exception of
TP53; Fig. 3A). In children with TS, an inferred network
was generated from all the associated genes (CDK4,
IGFBP3, KRAS, MYOD1, PIK3R3, PTPN1 and SOS1
with the exception of LHX4 and PPP1CB; Fig. 3B). Gene
expression data associated with first-year growth were
mapped onto the inferred networks (Fig. 3A and B). One
putative eQTL (a gene with both a genetic association
and a change in expression) was identified in GHD,
AKT1, and two putative eQTLs were identified in TS,
KRAS and MYOD1. Other inferred network genes were
also associated with changes in gene expression in
either or both low and high quartiles of first-yeargrowth (Fig. 3A and B), thus implying functional
changes correlated with the genetic associations.In silico prediction of functional
consequences of SNPs
Using the ENCODE database, in which transcription
factor binding has been assessed in multiple cell lines
by ChIP-seq, the SNPs in IGFBP3, GRB10, CYP19A1
and LHX4 fall within, or close to, transcription binding
sites (Table 5).Discussion
GH is widely used to treat a range of growth disorders.
Children who are sensitive to r-hGH in the first year of
treatment and grow well are more likely to continue to
gain height in the long-term (20, 21, 22). Identification
of those who will be either sensitive or, more
importantly, insensitive to r-hGH has important impli-
cations for counseling and clinical management.
Current models to predict growth response to r-hGH
over the first years of treatment have been based
primarily on baseline auxologic characteristics and
r-hGH dose, the latter being the only predictor that
the treating physician can modulate (20, 21, 22); some
models also include baseline IGF1 and IGFBP3 levels
(both being GH-dependent biomarkers) and short-term
change in bone markers (23, 24). In GHD, models based
on auxology can predict up to 65% of the variability in
the first year, and with the addition of biochemical
markers, this is increased to 85%. In non-GH-deficient
conditions, such models predict no more than 40–52%
of the variability in first-year response; these predictions
often have low accuracy (22). The PREDICT study is
the first long-term study to evaluate the extent to
which a range of genetic markers are associated with
growth response.
For the DNA studies, a candidate gene approach was
adopted, picking genes that affect the growth process
not only directly but also indirectly by affecting
metabolic pathways. Two very different growth
disorders were examined, namely GHD, in which the
cause was undefined, and TS, in which there waswww.eje-online.org
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Figure 1 (A and C) The first and second principal components
(PCs), based on a PC analysis undertaken on Tag single nucleotide
polymorphisms for children with (A) GH deficiency (GHD) and (C)
Turner syndrome (TS). The first PC clearly demarcates children
from Asian countries vs children from all other countries. (B and D)
The relationship between first-year growth response and the first
PC in children with (B) GHD and (D) TS. There is complete overlap
in growth response between children from Asian countries vs
children from all other countries. The same overlap occurs with the
second PC (data not shown). Countries are Argentina, Australia,
Austria, Canada, France, Germany, Italy, Korea, Norway, Russia,
Spain, Sweden, Taiwan and UK.
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www.eje-online.orgabsence or structural abnormality of one X chromo-
some. The majority of the SNPs associated with first-year
response to r-hGH differed between these conditions,
implying that the genetic influences on the action of
exogenous GH are not the same in the two conditions. In
addition, this difference may relate to a ‘replacement’ GH
dose in GHD vs a ‘pharmacologic’ dose in TS. However,
SNPs in two genes, IGFBP3 and SOS1, were common to
both conditions, and these genes may have an impact on
r-hGH sensitivity independent of the etiology of the
growth disorder. Importantly, the differences in growth
associated with the SNPs shown in Table 2 are of
sufficient magnitude to be clinically important, account-
ing forw20% of the first-year response in this study.
Short stature associated with GHD without a defined
etiology covers a broad spectrum, ranging from those
with severe GHD, low IGF1 levels and very poor growth
performance through to those with a mild impairment of
GH secretion and low–normal IGF1, who in the majority
of cases re-test as GH sufficient in late adolescence. This
is the range of children who are treated as GHD, and if
pharmacogenomics is going to aid the management of
such children, then the genes associated with growth
response to r-hGH must be significant across this broad
diagnostic range. The PREDICT GHD cohort reflects this
range of deficiency within the GH–IGF axis; children
with severe GHD are represented, but also children with
a modest impairment of GH secretion with normal IGF1
and IGFBP3 serum levels. It is also important to control
for other confounding factors including age, r-hGH dose,
pubertal progress, compliance and ethnic background.
Therefore, we stratified the patients by age for the
categorical analysis, using three age groups, each
associated with quartiles of response. This identified
some additional genes that were associated with growth
response, more so in TS than GHD (Table 3). In the first
month of this study, the dose of r-hGH to be given to
children with GHD and TS was specified; thereafter, the
clinicians determined the dose most appropriate for their
patient. It was reassuring to find that the dose of r-hGH
in both conditions was the same across the quartiles of
growth response (Table 4), indicating that the dose was
unlikely to be a major confounding factor. All were
prepubertal at baseline, with approximately one-third
entering the first stages of puberty by the end of the first
year. This may have impacted modestly on growth rate
in girls but not in boys. Compliance, as assessed by recall
of injections given over the last month, was high in both
conditions (meanw90%). It is very difficult to know the
reliability of these data, and it is likely that this is a
significant overestimation of compliance. It is well
recognized that SNP frequencies vary between ethni-
cities, and this proved to be the case in this study with
children from countries in South Asia separating very
clearly from children from all other countries in the
study when applying PCA to Tag SNPs (Fig. 1A and C).
Nevertheless, this did not influence the magnitude of
AUTHOR COPY ONLY
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Figure 2 ‘Heat map’ of genes associated with
first-year growth response to r-hGH in (A)
children with GH deficiency (GHD) and (B)
girls with Turner syndrome (TS). Each
column (x-axis) represents an individual child
(with growth rate (cm) shown), and each row
(y-axis) represents an individual gene. Red
color in a cell indicates increased gene
expression and green color in a cell rep-
resents decreased gene expression in the
lowest quartile vs the rest. The box indicates
the expression profiles of those in the lowest
quartile. The ‘dendrogram’, which groups
‘clusters’ of genes with similar expression
levels, is shown on the left side of each figure.
Low Q, lowest quartile (%Q1).
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and D).
We also used a whole genome approach by analyzing
gene expression profiles at baseline, using whole blood
mRNA; the use of a PBMC model for variation of gene
expression in response to r-hGH has previously been
validated (11, 12). Gene expression signatures associ-
ated with both low and high growth responses in GHD
and TS have been defined. In this study, genes related to
growth factor action, signal transduction and cell cycle
regulation were identified, emphasizing that many
cellular processes affect response to r-hGH. In order to
examine the potential functionality of the SNPs, we have
looked at their proximity to transcription factor binding
sites (Table 5). One of the IGFBP3 SNPs (rs10255707) is
located within an early growth response 1 (EGR1)
binding site. EGR1 is a zinc-finger, nuclear protein that
functions as a regulator of transcription, with studies
suggesting that it is a cancer suppressor gene (gene ID:
http://www.ncbi.nlm.nih.gov/gene/1958).
The principal carrier protein for IGF1, IGFBP3, whose
expression is GH-dependent, was identified in both
conditions (Tables 2 and 3B). IGF1 SNPs were not
identified. This implies that IGFBP3 could have a greater
overall impact on the variability of growth responses tor-hGH than IGF1. At the cellular level, IGFBP3 has both
IGF1-dependent and direct, IGF1-independent effects on
cell growth regulation (25). For the rs3110697 IGFBP3
SNP, which is within 200 bp of STAT3 and EGR1 binding
sites on the IGFBP3 gene (Table 5), carriage of the G
allele in GHD was associated with a high growth
response (Table 2), but in girls with TS, carriage of the
GG genotype was associated with a low growth response
(Table 3B). These genotypes have been shown to
associate with different serum levels of IGFBP3 in an
adult multi-ethnic cohort (26); lowest levels were
reported in those carrying the AA genotype, and 17%
higher levels were found in those with a GG genotype.
Thus, in GHD, a low growth response would associate
with a relatively low IGFBP3 serum level, while in TS, a
higher growth response would associate with low
IGFBP3 levels. These apparently conflicting data are,
however, supported by other clinical data; in a study
assessing parameters that determine growth response on
r-hGH treatment in GHD, IGFBP3 SDS was shown to
have a positive relationship with change in height SDS
(27). In a pharmacogenomic study examining the impact
of an IGFBP3 SNP that also affects serum IGFBP3 in GHD,
genotypes associated with higher IGFBP3 levels were
associated with greater growth responses (28). Inwww.eje-online.org
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Figure 3 Biologic networks inferred from
genes associated with growth response in
children with (A) GH deficiency (GHD) and (B)
Turner syndrome (TS). Blue shading indicates
genes found to be associated with growth
response in this study; orange shading
indicates genes within the network associated
with differences in baseline expression;
orange/blue shading represents putative
eQTLs, where there is both a genetic
association and a change in gene expression;
white shading represents genes in the inferred
network, which have not been directly
associated with growth response or gene
expression difference. The tables show gene
expression differences when comparing low
growth response (quartile,Q1 vs Q2–Q4) and
high growth response (quartile,Q4 vsQ1–Q3)
; green cells of the table represent
downregulated gene expression; red cells of
the table represent upregulated gene
expression and gray cells of the table
represent no change in gene expression.
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in prediction models for response to r-hGH in children
who are small for gestational age (23). In addition, in an
ex vivo fibroblast model of growth factor action, TS cells
produced more IGFBP3 than control cells in the basal
state, but generated less IGFBP3 in response to IGF1
stimulation, implying that higher IGFBP3 levels in the
media around these cells were inhibiting IGF1 action
(29). Therefore, the influence of IGFBP3 appears to be
disease dependent, and this is reflected in the divergent
growth responses associated with the same IGFBP3 SNP
in GHD and TS. These differing associations may be due
to the different r-hGH doses received by patients with
GHD and TS (larger in TS), as well as differences in
growth plate resistance to GH and/or IGF1.
In patients with GHD, six SNPs in GRB10 were
associated with growth response (Tables 2 and 3A).
GRB10 interacts with insulin and IGF1 receptors; its
overexpression inhibits tyrosine kinase receptors lead-
ing to growth suppression (gene ID: http://www.ncbi.
nlm.nih.gov/gene/2887). Two of the SNPs are within
200 bp of transcription factor binding sites and would
be predicted to have an effect on transcriptional
regulation (Table 5). The SNP in the CYP19A1 gene is
located within a Fos–Jun site and has been shown towww.eje-online.orgimpact transcriptional activity – the C allele had 60%
higher promoter activity than the A allele (30). Growth
rate in GHD was lower in TT homozygotes, implying
that lower aromatase activity would associate with
poorer growth responses. This observation suggests that
even before puberty, low levels of estrogen may
contribute to growth response to r-hGH.
In girls with TS, the transcription factor LHX4, which
when mutated is associated with multiple pituitary
hormone deficiencies, was associated with growth
response. Girls with TS have normal endogenous GH
secretory capacity. However, this SNP is located within
200 bp of a CTCF-binding site; CTCF is another zinc-
finger protein known to regulate transcription (Table 5).
This association may suggest a role for regulation of
pituitary hormones in first-year response to r-hGH
treatment in TS. In addition to IGFBP3, SNPs identified
in both conditions included genes within the MAPK
pathway – SOS1 and SOS2 in GHD, and SOS1 and KRAS
in TS. SOS1 and KRAS, but not SOS2, have been
implicated in human rasopathies, including mutations
in SOS1 and KRAS in Noonan syndrome and KRAS
mutations in cardiofaciocutaneous syndrome (31). This
indicates that the MAPK pathway is a key regulator of
r-hGH responsiveness.
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Table 5 Physical association of significant SNPs in continuous and categorical analyses in (A) GHD and (B) TS
to known transcription factor binding sites.
Gene SNP Transcription factor binding sitesa
(A) GHD
GRB10 rs1024531 Within 200 bp of ‘Neurone-restrictive Silencer factor’ (NRSF) site
rs12536500 Within 200 bp of ‘Upstream Regulatory factor’ (USF) half site
CYP19A1 rs10459592 Within Fos/Jun site
IGFBP3 rs3110697b Within 200 bp of STAT3 and EGR1 sites
rs10255707 Within EGR1 site
CYR61 rs9658584 Within P300/JUN/KAP1 sites
AKT1 rs1130214 Within CTCF/Rad21 sites
(B) TS
LHX4 rs3845395 Within 200 bp of CTCF site
rs4652492 Within 200 bp of CTCF/Rad21 sites
PIK3R3 rs809775 Within 200 bp of STAT3 site
CDK4 rs2069502 Within 200 bp of CTCF site
SOS1 rs2168043 Within CEBPB site
IGFBP3 rs3110697b Within 200 bp of STAT3 and EGR1 sites
Bp, base pairs; GHD, GH deficiency; SNP, single nucleotide polymorphism; TS, Turner syndrome.
aThese data have been derived from many different cell lines of which transcription factors and their binding sites responsible for
modulating gene transcription, as identified by ChIP-seq, are listed in the ENCODE database (http://genome.ucsc.edu/
ENCODE/). The SNPs identified in this study lie in or near these binding sites.
bSame SNP found in both GHD and TS.
Genetic markers for growth response in GHD or TS 287EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013) 169Using a network approach to analysis, we have
shown that genes within networks associated with
growth response are differentially expressed between
high and low responders to r-hGH in both TS and GHD
(Fig. 3). Importantly, the latter included three genes
containing SNPs associated with growth response (one
in GHD, two in TS), demonstrating that these SNPs are
associated with a change in expression in that gene.
This study has identified potential genetic markers
and expression profiles for growth response to r-hGH in
patients with GHD or TS, and has broadened consider-
ably the spectrum of genes associated with GH action.
These findings must be validated in independent
cohorts, including the full range of growth disorders
treated with r-hGH. These results indicate that pharma-
cogenomics could have a role to play in a personalized
strategy for managing r-hGH treatment in children.Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.
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